News Releases
Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye Drugs
January 14, 2025 – Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRose, Inc., Provectus’s Founded Entity that is developing novel ocular therapeutics.
VisiRose Announces $3 Million Seed Financing Round to Advance Ocular Therapeutics
January 14, 2025 — VisiRose Inc. today announced the closing of a $3 million seed financing round.
Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology
Dec 11, 2024 - Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the launch of VisiRose, Inc. (“VisiRose”), Provectus’s first Founded Entity.
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections
Dec 10, 2024 - VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI).
Bascom Palmer Eye Institute Ranked Nation's No. 1 in Ophthalmology for 23rd Time
July 16, 2024 - For the 23rd time, Bascom Palmer Eye Institute, part of the University of Miami Health System and the University of Miami Miller School of Medicine, has been ranked the nation’s Best in Ophthalmology by U.S. News & World Report in its annual Best Hospitals survey.
Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium
March 27, 2024 - New Provectus Spinout Company Would Commercialize Combination Therapy of University’s Light Source Medical Device and Provectus’s Pharmaceutical-Grade Rose Bengal Sodium